---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-060092"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:12:29.037602+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial

## Summary
- Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.
- APOLLO study previously reported 78% objective response (7/9) and 44% complete response (4/9) at 4 weeks post MT-601 infusion.
- Cellipont to provide technology transfer and cGMP manufacturing services over approximately nine months to support clinical supply.
- Collaboration designed to enable potential pivotal trial and commercial readiness; Cellipont facility in The Woodlands, TX.

## SEC filing metadata
- accession: 0001104659-25-060092
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925060092/0001104659-25-060092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925060092/tm2518163d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-060092
- JSON: https://secwatch.observer/filing/0001104659-25-060092.json
- Plain text: https://secwatch.observer/filing/0001104659-25-060092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.